Patient experiences with inhaled levodopa for OFF episodes in Parkinson's disease
Observes how people with Parkinson's disease experience inhaled levodopa for OFF episodes.
Plain-language title generated from the registry record
Registry title: Real-world Patient Experiences With Inbrija®
Key facts
- Where
- Altmünster and Graz, AustriaSee the 2 sites
Where in Austria
- Neurologisches Therapiezentrum Gmundnerberg GmbHAltmünster, AustriaNot yet recruiting
- Medizinischen Universität GrazGraz, AustriaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Merz Therapeutics GmbH
- Trial code
- NCT07797790
- Record updated
- 2 October 2026
- Original description
Parkinson's disease can cause OFF episodes, when medication effects wear off and symptoms return, affecting movement, daily activities, comfort, and wellbeing. This study aims to explore the experiences of people with Parkinson's disease who are prescribed Inbrija® as part of their usual care. Through a mixed-methods approach, the study will examine how OFF episodes affect patients, what influences their decision to use Inbrija®, and whether patient-reported outcomes related to symptoms, daily functioning, and quality of life change during the first 3 months of treatment.Read full original descriptionShow less
Real-world Patient Experiences With Inbrija® - Non-interventional Assessment of Inhaled Levodopa for the Management of OFF Episodes in Parkinson's Disease: a Mixed-methods Study
Parkinson's disease can cause OFF episodes, when medication effects wear off and symptoms return, affecting movement, daily activities, comfort, and wellbeing. This study aims to explore the experiences of people with Parkinson's disease who are prescribed Inbrija® as part of their usual care. Through a mixed-methods approach, the study will examine how OFF episodes affect patients, what influences their decision to use Inbrija®, and whether patient-reported outcomes related to symptoms, daily functioning, and quality of life change during the first 3 months of treatment.
The study is planned to be conducted at approximately 7 sites in Austria, Germany, and Sweden and will enroll up to 120 participants receiving Inbrija® in routine clinical practice.
Inclusion: Adults aged 18 years or older; Diagnosis of Parkinson's disease with a history of OFF episodes; Able and willing to provide informed consent; For the Quantitative Component:; Physician decision to initiate Inbrija® for the treatment of OFF episodes in Parkinson's disease according to routine clinical practice prior to enrollment; For the Qualitative Component:; Current user of Inbrija® for OFF episodes in Parkinson's disease according to approved prescribing conditions; At least 6 weeks of regular Inbrija® use (minimum 4 uses during the previous month); Able to participate in a 60-minute interview using an internet-enabled device.
Exclusion: Previous use of Inbrija® before study enrollment; Participation in an interventional Parkinson's disease clinical trial within 3 months prior to Inbrija® initiation; Participation in an interventional Parkinson's disease clinical trial within 3 months prior to enrollment; For the Quantitative Component:; Residence outside Austria, Germany, or Sweden; Current use of an on-demand treatment for OFF episodes other than Inbrija®; For the Qualitative Component:; Residence outside Austria or Germany; Current use of an on-demand treatment for OFF episodes other than Inbrija®.